Finerenone Benefits Extend Across CKD Etiologies in 14,574-Patient Pooled Analysis
This individual participant data pooled analysis of three placebo-controlled trials tests whether finerenone's kidney and cardiovascular benefits hold beyond diabetic kidney disease, informing mineralocorticoid receptor antagonist selection in nephrology practice.
📅 Journal publication: Jun 13, 2026(online Jun 5, 2026)·Last updated: Nov 18, 2026
Finerenone cuts kidney decline risk by nearly a quarter.
Chronic kidney disease (CKD) is a major public health issue, and effective treatments are needed to prevent progression. Finerenone reduced the risk of kidney and cardiovascular outcomes by 24% and 20%, respectively, compared to placebo. The study supports the use of finerenone regardless of CKD aetiology and baseline conditions, though hyperkalaemia is a consideration. Finerenone effectively reduces CKD progression and cardiovascular risks across diverse patient populations.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Neuen BL, Heerspink HJL, Perkovic V, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Jongs N, Smeijer JD, Brinker M, Ahlers C, Lage A, Horvat-Bröcker A, Schloemer P, Eissing T, Dayoub R, Lawatscheck R, Agarwal R, FIND-CKD, FIDELIO-DKD and FIGARO-DKD Investigators
Citation:Neuen BL, Heerspink HJL, Perkovic V, et al. Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY). Lancet (London, England). 2026;407(10546):2375-2386. doi:10.1016/S0140-6736(26)01009-3